<DOC>
	<DOC>NCT00281632</DOC>
	<brief_summary>This study was designed to find out how effective and safe GW786034, is in the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer that has not responded to standard treatment.</brief_summary>
	<brief_title>A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>Inclusion criteria: Confirmed diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Has received one prior platinumbased chemotherapy regimen(cisplatin,carboplatin, or oxaliplatin). Has psychological, familial, sociological or geographical condition that does not permit compliance with the protocol. Is on a specifically prohibited medication or requires these medications during treatment with GW786034. Exclusion criteria: Has had any surgery, chemotherapy, hormonal therapy, biologic, immunotherapy, or radiotherapy with in the last 28 days and has not recovered from such prior therapy. Poorly controlled hypertension(systolic 140mmHg or higher or Diastolic 90mmHg or higher). Currently taking warfarin. Low molecular weight heparin and lowdose warfarin(1mg per day)is permitted.</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Pazopanib</keyword>
	<keyword>Fallopian tube cancer</keyword>
	<keyword>Ovarian epithelial cancer</keyword>
	<keyword>Peritoneal cancer</keyword>
</DOC>